Tacrolimus
| Evidence Level: L1 | Predicted Indications: 3 |
Table of Contents
Tacrolimus: From Atopic Dermatitis to Seborrheic Dermatitis
One-Sentence Summary
Tacrolimus (topical formulation, e.g. Protopic®) is an established treatment for atopic dermatitis, acting as a calcineurin inhibitor that suppresses T-cell-mediated skin inflammation. The TxGNN model predicts it may also be effective for Seborrheic Dermatitis, with 2 clinical trials and 20 publications currently supporting this direction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Atopic Dermatitis (topical calcineurin inhibitor therapy) |
| Predicted New Indication | Seborrheic Dermatitis |
| TxGNN Prediction Score | 99.26% |
| Evidence Level | L1 |
| UK Market Status | Not marketed |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Proceed with Guardrails |
Note: Formal UK regulatory data (approved indication text, MHRA licences) are not present in this Evidence Pack. The original indication above is drawn from the mechanistic and clinical-trial context within the supplied evidence, not from a UK marketing authorisation record.
Why is This Prediction Reasonable?
Detailed formal mechanism-of-action documentation was not supplied in this Evidence Pack (original_moa: Data Gap). However, the evidence pack’s own repurposing rationale confirms that tacrolimus acts by inhibiting the calcineurin/NFAT pathway, thereby suppressing antigen-specific T-cell activation and downstream release of pro-inflammatory cytokines. This is the same mechanism that underlies its established efficacy in atopic dermatitis.
Seborrheic dermatitis and atopic dermatitis are both chronic inflammatory skin conditions. Seborrheic dermatitis pathology involves Malassezia-triggered local immune inflammation and T-cell activation — a process mechanistically analogous to the T-cell-driven inflammation seen in atopic dermatitis. Because tacrolimus dampens this shared inflammatory cascade regardless of the triggering antigen, its anti-inflammatory action is plausibly transferable to seborrheic dermatitis.
This mechanistic plausibility is further reinforced by direct clinical evidence: completed Phase 3 and Phase 4 randomised trials have already tested topical tacrolimus specifically as a maintenance therapy for severe facial seborrheic dermatitis, with results demonstrating reduced relapse frequency and reduced need for topical steroids. Mechanism and clinical evidence therefore converge on the same conclusion.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrolment | Key Findings |
|---|---|---|---|---|
| NCT02004860 | Phase 3 | Completed | 120 | Evaluated tacrolimus ointment (Protopic®) as a maintenance treatment for severe facial seborrheic dermatitis, aiming to prolong remission and reduce reliance on topical steroids. |
| NCT01591070 | Phase 4 | Completed | 104 | Assessed proactive once- or twice-weekly application of 0.1% tacrolimus ointment to maintain remission and reduce exacerbation of adult facial seborrheic dermatitis. |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 26512166 | 2015 | RCT/Clinical Study | Annals of Dermatology | 0.1% tacrolimus ointment used as maintenance therapy for facial seborrheic dermatitis, following the intermittent maintenance model established in atopic dermatitis. |
| 24171300 | 2013 | RCT (comparative) | Annals of Parasitology | Compared sertaconazole 2% cream with tacrolimus 0.03% cream in 60 seborrheic dermatitis patients. |
| 33010323 | 2021 | RCT (double-blind, multicentre) | J Am Acad Dermatol | Tacrolimus 0.1% vs ciclopiroxolamine 1% as maintenance therapy for severe facial seborrheic dermatitis; first long-term maintenance therapy formally tested for this condition. |
| 37067129 | 2023 | RCT | Indian J Dermatol Venereol Leprol | Compared oral itraconazole plus topical tacrolimus against topical tacrolimus alone for maintenance treatment of seborrheic dermatitis in Vietnam. |
| 39219446 | 2024 | Cochrane Systematic Review/NMA | Clin Exp Allergy | Network meta-analysis of topical anti-inflammatory treatments for eczema, including calcineurin inhibitors such as tacrolimus. |
| 27804089 | 2017 | Systematic Review | Am J Clin Dermatol | Systematic review of topical treatments for facial seborrheic dermatitis, covering antifungal agents, keratolytics and corticosteroids. |
| 19222250 | 2009 | Review | Am J Clin Dermatol | Reviews the pathophysiology, safety and efficacy of topical calcineurin inhibitors (including tacrolimus) in seborrheic dermatitis. |
| 12833030 | 2003 | Open pilot study | J Am Acad Dermatol | Open-label pilot study of 18 patients treated with 0.1% tacrolimus for seborrheic dermatitis; 61% achieved complete clearance. |
| 28685715 | 2017 | Cohort | Chinese Medical Journal | Investigated Staphylococcus epidermidis colonisation and skin barrier impairment in facial seborrheic dermatitis, relevant to disease mechanism. |
| 19213227 | 2009 | Review | J Drugs Dermatol | Overview of facial seborrheic dermatitis pathophysiology and therapeutic horizons, including calcineurin inhibitor therapy. |
UK Market Information
Tacrolimus currently holds no UK marketing authorisation in this Evidence Pack (market status: Not marketed; 0 licences on record). No product-specific authorisation table can be generated at this time.
Safety Considerations
Please refer to the SmPC and BNF for safety information. Report suspected adverse reactions via the Yellow Card Scheme.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: The evidence level is L1, supported by completed Phase 3 and Phase 4 randomised trials directly testing tacrolimus as maintenance therapy for seborrheic dermatitis, alongside a strong mechanistic rationale (calcineurin/NFAT inhibition shared with the approved atopic dermatitis indication). However, the drug currently has no UK marketing authorisation, and critical safety documentation is missing.
To proceed, the following is needed:
- UK SmPC/label warnings and contraindications (currently a blocking data gap — required before any safety assessment)
- Confirmed mechanism-of-action documentation from DrugBank or equivalent source
- UK marketing authorisation pathway assessment, since tacrolimus is not currently marketed in the UK
- Drug–drug interaction data (none currently on file)
- A formulation/route compatibility review to confirm topical dosage forms align with the seborrheic dermatitis indication
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.